Comparative Pharmacology
Head-to-head clinical analysis: CHLOROTHIAZIDE SODIUM versus HYDRALAZINE HYDROCHLORIDE W HYDROCHLOROTHIAZIDE 25 25.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHLOROTHIAZIDE SODIUM versus HYDRALAZINE HYDROCHLORIDE W HYDROCHLOROTHIAZIDE 25 25.
CHLOROTHIAZIDE SODIUM vs HYDRALAZINE HYDROCHLORIDE W/ HYDROCHLOROTHIAZIDE 25/25
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits sodium-chloride symporter in distal convoluted tubule of nephron, reducing sodium reabsorption and promoting diuresis.
Hydralazine is a direct-acting arteriolar vasodilator that reduces peripheral resistance through relaxation of vascular smooth muscle, likely via nitric oxide-mediated increases in cGMP. Hydrochlorothiazide is a thiazide diuretic that inhibits the Na+/Cl- cotransporter in the distal convoluted tubule, reducing sodium and water reabsorption and decreasing plasma volume.
500 mg to 1 g orally or intravenously once or twice daily.
One tablet orally twice daily, titrated based on blood pressure response; maximum dose: one tablet four times daily.
None Documented
None Documented
Terminal elimination half-life is 45–120 minutes in patients with normal renal function; prolonged in renal impairment (up to 24 hours in anuria).
Hydralazine: 2-8 hours (terminal half-life; prolonged in renal impairment; acetylator phenotype affects clearance); Hydrochlorothiazide: 6-15 hours (terminal half-life; increased in renal impairment).
Primarily renal excretion via tubular secretion; approximately 95% of absorbed dose excreted unchanged in urine within 24 hours, with less than 5% eliminated via bile/feces.
Hydralazine: 80% renal (as metabolites, 5-10% unchanged); Hydrochlorothiazide: 95% renal (as unchanged drug).
Category C
Category A/B
Thiazide Diuretic
Thiazide Diuretic